Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejpb.2021.04.003 http://scihub22266oqcxt.onion/10.1016/j.ejpb.2021.04.003 33852968!ä!33852968 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33852968&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Pharm+Biopharm 2021 ; 163 (ä): 198-211 Nephropedia Template TP {{tp|p=33852968|t=2021. Oral inhalation for delivery of proteins and peptides to the lungs |pdf=|usr=}}{{33852968}} gab.com Text Oral inhalation for delivery of proteins and peptides to the lungs JO: Eur J Pharm Biopharm http://www.kidney.de/pget.php?&tw=1&pmid=33852968 #FOAvip Oral inhalation is the preferred route for delivery of small molecules to the lungs, because high tissue levels can be achieved shortly after application. Biologics are mainly administered by intravenous injection but inhalation might be beneficial for the treatment of lung diseases (e.g. asthma). This review discusses biological and pharmaceutical challenges for delivery of biologics and describes promising candidates. Insufficient stability of the proteins during aerosolization and the biological environment of the lung are the main obstacles for pulmonary delivery of biologics. Novel nebulizers will improve delivery by inducing less shear stress and administration as dry powder appears suitable for delivery of biologics. Other promising strategies include pegylation and development of antibody fragments, while carrier-encapsulated systems currently play no major role in pulmonary delivery of biologics for lung disease. While development of various biologics has been halted or has shown little effects, AIR DNase, alpha1-proteinase inhibitor, recombinant neuraminidase, and heparin are currently being evaluated in phase III trials. Several biologics are being tested for the treatment of coronavirus disease (COVID)-19, and it is expected that these trials will lead to improvements in pulmonary delivery of biologics. Twit Text FOAVip Oral inhalation for delivery of proteins and peptides to the lungs ????Eur J Pharm Biopharm http://www.kidney.de/pget.php?&tw=1&pmid=33852968 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33852968 #FOAvip English Wikipedia <ref>{{Cite pmid|33852968}}</ref> Oral inhalation for delivery of proteins and peptides to the lungs #MMPMID33852968 Frohlich E; Salar-Behzadi S Eur J Pharm Biopharm 2021[Jun]; 163 (ä): 198-211 PMID33852968show ga Oral inhalation is the preferred route for delivery of small molecules to the lungs, because high tissue levels can be achieved shortly after application. Biologics are mainly administered by intravenous injection but inhalation might be beneficial for the treatment of lung diseases (e.g. asthma). This review discusses biological and pharmaceutical challenges for delivery of biologics and describes promising candidates. Insufficient stability of the proteins during aerosolization and the biological environment of the lung are the main obstacles for pulmonary delivery of biologics. Novel nebulizers will improve delivery by inducing less shear stress and administration as dry powder appears suitable for delivery of biologics. Other promising strategies include pegylation and development of antibody fragments, while carrier-encapsulated systems currently play no major role in pulmonary delivery of biologics for lung disease. While development of various biologics has been halted or has shown little effects, AIR DNase, alpha1-proteinase inhibitor, recombinant neuraminidase, and heparin are currently being evaluated in phase III trials. Several biologics are being tested for the treatment of coronavirus disease (COVID)-19, and it is expected that these trials will lead to improvements in pulmonary delivery of biologics. |Administration, Inhalation[MESH] |Administration, Oral[MESH] |Animals[MESH] |Biological Products/administration & dosage[MESH] |Drug Carriers/chemistry[MESH] |Drug Delivery Systems/methods[MESH] |Humans[MESH] |Lung Diseases/*drug therapy[MESH] |Lung/*drug effects[MESH] |Nebulizers and Vaporizers[MESH] |Peptides/*administration & dosage[MESH] |Powders/administration & dosage[MESH]Oral inhalation for delivery of proteins and peptides to the lungs (epmc).pdf DeepDyve Pubget Overpricing